Ocugen, Inc.
Ocugen (OCGN) announced its gene therapy OCU400 received provisional approval in the Bahamas, aiming to treat the first retinitis pigmentosa patient within 90 days. Shares rose 3%. The company expects Phase 3 trial results in Q1 2027 and a U.S. BLA submission in Q2. Ocugen has other late-stage eye-disease programs and expects cash runway through 2028.
Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 21, 2026, Ocugen, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) virtually, which was adjourned to October 5, 2026 solely with respect to the proposal to approve the a
Musunuri Shankar (Chief Executive Officer) sold 468,727 shares of Ocugen, Inc. (OCGN) at $1.12 ($0.52M total) on 2026-09-09 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning OCGN (Ocugen, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent OCGN coverage spans regulation, insider activity and technology.
In the last 30 days, OCGN insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($589K). The most active reporter was Musunuri Shankar, Chief Executive Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The Bahamas approval expands access outside the U.S. and may boost investor sentiment.
Potential dilution may pressure the stock price if the additional shares are issued.
Insider sale may signal reduced confidence, potentially pressuring the stock short-term.
High upside target could spark speculative buying.
Positive regulatory progress and trial initiation may lift sentiment for Ocugen.
AlphAI scores every news story that mentions OCGN with an AI model for sentiment and relevance, and aggregates insider trades from Ocugen, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocugen (OCGN) announced its gene therapy OCU400 received provisional approval in the Bahamas, aiming to treat the first retinitis pigmentosa patient within 90 days. Shares rose 3%. The company expects Phase 3 trial results in Q1 2027 and a U.S. BLA submission in Q2. Ocugen has other late-stage eye-disease programs and expects cash runway through 2028.
2 min readOcugen, Inc. (OCGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 21, 2026, Ocugen, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) virtually, which was adjourned to October 5, 2026 solely with respect to the proposal to approve the a
1 min readMusunuri Shankar (Chief Executive Officer) sold 468,727 shares of Ocugen, Inc. (OCGN) at $1.12 ($0.52M total) on 2026-09-09 under a Rule 10b5-1 trading plan.
1 min readAnalysts maintained Buy ratings on Zymeworks (ZYME), Axsome Therapeutics (AXSM), and Ocugen (OCGN). ZYME's PT is $38 (Citi) and $40.20 (consensus). AXSM's PT is $256 (Wells Fargo) and $291 (consensus). OCGN's PT is $12 (Noble Financial) and $10.13 (consensus). All have Strong Buy consensus.
2 min readKowa Pharmaceuticals' NDA for K-911, an IOP-lowering eye drop, was accepted by the FDA, with a PDUFA target date of April 30, 2027. Ocugen dosed the first patient in a Phase 3 trial for OCU410, a gene therapy for dry AMD. Bausch + Lomb surveyed awareness of dry eye in menopause, finding low recognition. ASCRS announced events and policy statements. Research highlighted KLEx-CXL outcomes and enVista Aspire IOL performance.
2 min readOcugen, Inc. (OCGN) shares fell slightly as the company announced the first patient was dosed in a global Phase 3 trial for OCU410, a gene therapy candidate for dry age-related macular degeneration. The FDA granted OCU410 RMAT designation, potentially accelerating development. Ocugen aims to offer a one-time treatment for the condition, with no approved treatments outside the U.S. and limited options in the U.S.
2 min readOcugen, Inc. (OCGN) shares fell slightly as the company announced the first patient was dosed in its global Phase 3 trial for OCU410, a gene therapy for dry age-related macular degeneration. The FDA granted RMAT designation to OCU410, potentially accelerating development. The trial follows a successful End-of-Phase 2 meeting with the FDA.
1 min readOcugen, Inc. (OCGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ocugen Provides Business Update with Second Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET · Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry ag
6 min readOcugen (NASDAQ: OCGN) said it signed a binding term sheet to negotiate an exclusive license for its OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa with Roots Pharmaceutical and Al-Dhow International Holding. Ocugen expects up to $4 million in upfront and near-term milestones, up to $255 million in sales milestones, and 22% royalties on net sales. Ocugen will manufacture OCU400, with a definitive deal expected within 90 days.
4 min readJohnson-Greene Treerita Essalima (Chief Financial Officer) purchased 21,000 shares of Ocugen, Inc. (OCGN) at $1.23 on 2026-06-15.
2 min read
